Results 191 to 200 of about 11,697,511 (307)

ON THE TREATMENT OF CANCER [PDF]

BMJ, 1903
openaire   +2 more sources

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Colorectal Cancer Treatment During Pregnancy. [PDF]

J Adv Pract Oncol
Green KL, Hatch R.
europepmc   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Envafolimab - novel anti-PD-1/PD-L1 antibody in cancer treatment. [PDF]

Front Immunol
Kciuk M, Kołat D, Wanke K, Kontek R.
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Racial Differences in Breast Cancer Treatment and Information Access. [PDF]

J Surg Oncol
Williams T, Li MX, Fine KS, Melnick BA, Ho KC, Joseph J, Allums J, Casas Fuentes RJ, Coles BM, Galiano RD.   +9 more
europepmc   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Statin Initiation and Mortality After Colorectal Cancer Treatment.

JAMA Netw Open
Woo HT, Shin A.
europepmc   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update. [PDF]

Cancer Med
Nath AD, Alam Y, Mim AM, Akter M, Gani MA, Alam KMK, Alam MN.   +6 more
europepmc   +1 more source